Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Liabilities (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Total Liabilities for 4 consecutive years, with $601.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 17.6% to $601.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $601.5 million through Dec 2025, up 17.6% year-over-year, with the annual reading at $601.5 million for FY2025, 17.6% up from the prior year.
  • Total Liabilities hit $601.5 million in Q4 2025 for Axsome Therapeutics, up from $595.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $601.5 million in Q4 2025 to a low of $73.9 million in Q1 2022.
  • Historically, Total Liabilities has averaged $382.2 million across 4 years, with a median of $399.5 million in 2023.
  • Biggest five-year swings in Total Liabilities: surged 275.52% in 2023 and later rose 17.6% in 2025.
  • Year by year, Total Liabilities stood at $221.9 million in 2022, then soared by 79.01% to $397.3 million in 2023, then grew by 28.75% to $511.5 million in 2024, then grew by 17.6% to $601.5 million in 2025.
  • Business Quant data shows Total Liabilities for AXSM at $601.5 million in Q4 2025, $595.5 million in Q3 2025, and $566.7 million in Q2 2025.